Paradigm Biocapital Advisors LP Cogent Biosciences, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $1.95 Billion
- Q1 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 8,963,655 shares of COGT stock, worth $43.2 Million. This represents 2.75% of its overall portfolio holdings.
Number of Shares
8,963,655
Previous 4,917,412
82.28%
Holding current value
$43.2 Million
Previous $38.4 Million
39.99%
% of portfolio
2.75%
Previous 1.46%
Shares
5 transactions
Others Institutions Holding COGT
# of Institutions
190Shares Held
111MCall Options Held
61.9KPut Options Held
223K-
Kynam Capital Management, LP Princeton, NJ9.11MShares$43.9 Million4.6% of portfolio
-
Commodore Capital LP New York, NY8.89MShares$42.9 Million5.22% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$35.1 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$33.6 Million10.05% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA6.23MShares$30 Million12.7% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $317M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...